**Name of journal: World Journal of Clinical Oncology**

**ESPS Manuscript NO: 8292**

**Columns: TOPIC HIGHLIGHT**

WJCO 5th Anniversary Special Issues (1): Lung cancer

Chronic obstructive pulmonary disease as a risk factor for lung cancer

Takiguchi Y *et al*. COPD and lung cancer

Yuichi Takiguchi, Ikuo Sekine, Shunichiro Iwasawa, Ryota Kurimoto, Koichiro Tatsumi

**Yuichi Takiguchi, Ikuo Sekine, Shunichiro Iwasawa, Ryota Kurimoto,** Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan

**Koichiro Tatsumi,** Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan

**Author contributions**: Takiguchi Y and Tatsumi K designed the investigation; Sekine I, Iwasawa S and Kurimoto R performed the literature searches; Takiguchi Y wrote the paper; all the authors analyzed the data, read the manuscript and approved its submission to the Journal.

**Supported by** The Ministry of Education, Culture, Sports, Science and Technology of Japan

**Correspondence to: Yuichi Takiguchi, Professor,** Department of Medical Oncology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba 260-8670 Japan. takiguchi@faculty.chiba-u.jp

**Telephone:** +81-43-2262806 **Fax:** +81-43-2262815

**Received:** December 23, 2013 **Revised:** January 27, 2014

**Accepted:** May 16, 2014

**Published online:**

**Abstract**

The association between chronic obstructive pulmonary disease (COPD) and lung cancer has long been a subject of intense debate. The high prevalence of COPD in elderly smokers inevitably strengthens their coincidence. In addition to this contingent coincidence, recent studies have revealed a close association between the two diseases that is independent of the smoking history; that is, the existence of COPD is an independent risk factor for the development of lung cancer. Molecular-based evidence has been accumulating as a result of the efforts to explain the underlying mechanisms of this association. These mechanisms may include the following: the retention of airborne carcinogens followed by the activation of oncogenes and the suppression of tumor suppressor genes; the complex molecular mechanism associated with chronic inflammation in the distal airways of patients with COPD; the possible involvement of putative distal airway stem cells; and genetic factors that are common to both COPD and lung cancer. The existence of COPD in patients with lung cancer may potentially affect the process of diagnosis, surgical resection, radiotherapy, chemotherapy, and end-of-life care. The comprehensive management of COPD is extremely important for the appropriate treatment of lung cancer. Surgical resections with the aid of early interventions for COPD are often possible, even for patients with mild-to-moderate COPD. New challenges, such as lung cancer CT screening for individuals at high risk, are now in the process of being implemented. Evaluating the risk of lung cancer in patients with COPD may be warranted in community-based lung cancer screening.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Chronic obstructive pulmonary disease; Airflow limitation; Inflammation; Lung cancer; Carcinogenesis; Cancer screening; Computed tomography screening; Early intervention

**Core tip:** This article reviews current perspectives on the epidemiological, clinical, and etiological problems associated with the coexistence of lung cancer and chronic obstructive pulmonary disease.

Takiguchi Y, Sekine I, Iwasawa S, Kurimoto R, Tatsumi K. Chronic obstructive pulmonary disease as a risk factor for lung cancer. *World J Clin Oncol* 2014; In press

**Available from: URL:**

**DOI:**

**INTRODUCTION**

Smoking causes many diseases including lung cancer and chronic obstructive pulmonary disease (COPD). These diseases usually affect relatively elderly individuals. Because of the rapidly aging populations of many developed countries, the number of patients with lung cancer and/or COPD is growing. Lung cancer is one of the leading causes of death in many countries and accounted for approximately 1.37 million deaths worldwide in 2008[[1](#_ENREF_1)]. As was extensively discussed in the Global Initiative of Chronic Obstructive Lung Disease (GOLD)[[2](#_ENREF_2)], accurate estimations of the prevalence and mortality of COPD are difficult. The prevalence of COPD in a specific region varies because of differences in the survey methods, diagnostic criteria and analytic approaches[[3](#_ENREF_3), [4](#_ENREF_4)], ranging from 7.8% to 19.7% of the total population[[2](#_ENREF_2)]. COPD is often a primary cause of death. However, COPD can also contribute to death from other diseases, such as pneumonia, ischemic hear diseases and heart failure, making it difficult to estimate the COPD-associated mortality rate. Meanwhile, the Global Burden of Disease Study has projected that COPD will become the third leading cause of death worldwide by 2020[[5](#_ENREF_5)].

Because of the high prevalence of both conditions and strong common risk factors associated with smoking, the coexistence of lung cancer and COPD is inevitably high. In addition, recent studies have uncovered a non-confounding association between COPD and lung cancer development, together with its molecular mechanisms[[6](#_ENREF_6), [7](#_ENREF_7)]. Investigating and resolving the problems of the coexistence of these two diseases is important in view of their clinical relevance; their interaction leads to worse outcomes. This article reviews the current perspectives on the epidemiological, clinical, and etiological problems associated with the coexistence of lung cancer and COPD.

**COEXISTENCE OF LUNG CANCER AND COPD ASSESSED ACCORDING TO PULMONARY FUNCTION**

Because of the high mortality associated with lung cancer, the proportion of deaths from lung cancer among patients with COPD can reasonably be considered to represent the coexistence of lung cancer among patients with COPD. As shown in Table 1, the causes of death reported in patients with COPD vary significantly among studies, and the proportion of deaths from lung cancer ranges from 4% to 33%[[8-16](#_ENREF_8)], presumably because of different patient characteristics and analytical methods. Among their investigation, a prospective study identified 731 deaths that occurred over 14.5 years out of 5,887 asymptomatic non-smoking individuals who had mild or moderate airflow limitations, with an average FEV1/FVC of 65.0% ± 6.1% and an average age of 48.4 ± 6.8 years. The primary cause of death was lung cancer, representing 33% of the total deaths[[16](#_ENREF_16)]. Three other prospective studies disclosed a high incidence of lung cancer development or mortality among patients with COPD or individuals with airflow limitations[[17-19](#_ENREF_17)]. Skillrud *et al*[[17](#_ENREF_17)] prospectively observed 113 individuals who had a %FEV1 of 70% or less by comparing them with 113 age-matched, sex-matched, occupation-matched, and smoking history-matched individuals with a %FEV1 of 85% or more. The 10-year cumulative rates of lung cancer development were 8.8% and 2.0% in the former and latter groups, respectively, resulting in a statistically significant difference (*P* = 0.024)[[17](#_ENREF_17)]. Kuller *et al*[[18](#_ENREF_18)] reported an increase in lung cancer mortality according to a reduction in the FEV1. The lung cancer mortality per 1,000 person-years was 3.02 and 0.43 in the lowest and highest quintiles of the FEV1, respectively, and this association was not weakened by adjustments for smoking factors[[18](#_ENREF_18)]. The relative risk of COPD or airflow limitations associated with lung cancer was therefore calculated to be 4.4 and 7.0 in the studies by Skillrud *et al*[[17](#_ENREF_18)] and Kuller *et al*[[18](#_ENREF_18)], respectively. In a large-scale prospective study involving 448,600 lifelong nonsmokers who were cancer-free at baseline and who had a 20-year follow-up period, Turner *et al*[[19](#_ENREF_18)] again found a significant association between lung cancer mortality and pulmonary emphysema, with a hazard ratio of 1.66 (95%CI: 1.06-2.59)[[19](#_ENREF_19)]. Wasswa-Kintu *et al*[[20](#_ENREF_19)] conducted a population-based meta-analysis to reveal that even a relatively small decrease in the FEV1 (approximately 90% of predicted) increased the risk of lung cancer by 1.3-fold in men (95%CI: 1.05-1.62) and 2.6-fold in women (95%CI: 1.30-5.31), concluding that even a modest reduction in the %FEV1 is a significant predictor of lung cancer, especially among women[[20](#_ENREF_20)].

**COEXISTENCE OF LUNG CANCER AND COPD ASSESSED BY CT IMAGES**

The National Lung Cancer Screening Trial (NLST) for annual low-dose CT screening reported a 20% decrease in lung cancer mortality among heavy smokers between the ages of 55 and 74 years[[21](#_ENREF_21)]. This great achievement has resulted in several established guidelines recommending low-dose CT lung cancer screening for individuals with defined conditions, and the time when screening will be implemented as a part of community health care is drawing closer[[22](#_ENREF_22)]. The more common use of chest CT examinations in asymptomatic individuals would increase the chance of detecting pulmonary diseases, including lung cancer and pulmonary emphysema. Because a definitive diagnoses of COPD and pulmonary emphysema are based on functional and pathological criteria, respectively, they cannot, by definition, be diagnosed using CT[[2](#_ENREF_2)]. Nevertheless, the presence of a substantially distributed low attenuation area (LAA) in the pulmonary fields strongly suggests pulmonary emphysema and COPD. In fact, Goddard *et al*[[23](#_ENREF_23)] proposed a scoring system, which is used worldwide, to evaluate pulmonary emphysema using CT.

Six studies, consisting of 2 cohort and 4 case-control studies, evaluating the relationship between CT-based emphysema and the risk of lung cancer have been published[[24-29](#_ENREF_24)], and Zurawska *et al*[[30](#_ENREF_30)] concisely reviewed these studies. The relative risk (RR) for lung cancer, according to CT-based emphysema assessed using semi-quantitative visual methods, ranged from 1.9 to 4.7, with a pooled RR of 2.34 (95%CI: 1.46-3.76). Using multivariate analyses adjusted for covariates including age, sex, and smoking status, the adjusted odds ratio for lung cancer, according to the CT-based detections of emphysema, ranged from 1.73 to 3.14. Mizuno *et al*[[26](#_ENREF_26)] analyzed CT images from 947 healthy individuals who underwent a low-dose CT screening and 256 patients with lung cancer. After adjusting for sex and age, 423 matched healthy individuals and 141 patients with lung cancer were extracted for inclusion in multivariate analyses, with stratification according to their smoking status. The results disclosed that many functional and CT image factors indicative of COPD (relative risks for lung cancer; 7.17 with FEV1/FVC < 70% and 3.63 with LAA score ≥ 1) or interstitial lung diseases (relative risks for lung cancer; 4.73 with %VC < 80%, 5.10 with a fibrosis score ≥ 1 and 2.71 with a GGA score ≥ 1) were also risk factors for coincident lung cancer in a manner that was independent of the smoking status (Table 2). These observations suggesting a close association between COPD and lung cancer seem to imply at least three possibilities: first, airflow limitation itself is a risk factor for the development of lung cancer; second, some putative inter-individual variations in the sensitivity to harmful substances, such as active smoking, passive smoking, air pollutants, and cooking oil fumes, may link COPD and lung cancer; and third, some specific genotypes may predispose individuals to both COPD and lung cancer.

**POSSIBLE MECHANISMS UNDERLYING THE COEXISTENCE OF LUNG CANCER AND COPD**

A growing volume of evidence suggests that some molecular mechanisms may link COPD and lung cancer. A genome-wide association study has uncovered some putative common loci responsible for both COPD and lung cancer[[31](#_ENREF_31)]. Taking advantage of such modern technologies, we are soon likely to benefit from abundant information regarding the molecular mechanisms involving the pathogenesis of COPD and lung cancer. The current major possible explanations are outlined below.

***Retention of airborne carcinogens because of airflow limitations may enhance carcinogenesis in the airways***

In this speculative scenario, the airflow limitations that result from COPD suppress the clearance of carcinogens from the airway, leading to cancer in the airway. This classical scenario is now decorated with modern technical terms including DNA repair errors, oncogene activations, impaired tumor suppressor genes, oncogenic microRNA, the involvement of epithelial-mesenchymal transition, and a wide variety of epigenetic alterations.

***Chronic inflammatory processes arising from COPD may enhance carcinogenesis in the airways***

An association between persistent chronic inflammation and cancer has long been recognized. Examples include the relationships between cirrhosis and hepatocellular carcinoma, inflammatory bowel disease and colorectal cancer, burns and squamous cell carcinoma of the skin, and dental prostheses and lingual cancer. Recently, the relationship between chronic inflammation and cancer has been explained by a series of processes in which unscheduled necrotic cell death as a result of inflammation causes subsequent epithelial proliferation resulting in the suppression of immunity[[32](#_ENREF_32)]. Meanwhile, a volume of evidence has proven that complex inflammatory processes involving many types of immune cells, cytokines, matrix metalloproteinases, reactive oxygen species, and growth factors cause tissue damage and remodeling. This phenomenon ultimately results in the development of COPD[[2](#_ENREF_2)]. These factors also contribute to the enhancement of carcinogenesis[[33](#_ENREF_33), [34](#_ENREF_34)]. Parimon *et al*[[35](#_ENREF_35)] observed a reduced lung cancer risk in patients using inhaled corticosteroids in a dose-dependent manner. This observation strongly supports the idea that the pathophysiology of COPD may enhance the development of lung cancer.

***Putative lung stem cells activated by chronic inflammation in patients with COPD may transform to lung cancer stem cells***

There is no evidence supporting the existence of lung stem cells in humans or cancer stem cells in human lung cancer[[36](#_ENREF_36)]. However, Kim *et al*[[37](#_ENREF_37), [38](#_ENREF_38)] has reportedly identified bronchioalveolar stem cells in mice. If distal lung stem cells exist in humans, chronic inflammatory stimuli as a result of COPD might activate and transform these lung stem cells into lung cancer stem cells[[7](#_ENREF_7)].

***Genetic backgrounds common to both COPD and the development of lung cancer may exist***

A deficiency or decrease in alpha-1 antitrypsin is known to increase the risk of lung emphysema development. This condition, acting directly or indirectly through tissue damage to the lung, also increases the risk of lung cancer development[[39-42](#_ENREF_39)], although some controversy regarding this point still exists[[43](#_ENREF_43)]. Smoking is the strongest definitive risk factor for lung cancer development. Tobacco-derived pro-carcinogens are activated to become carcinogenic by a cluster of phase I enzymes. These activated carcinogens are then degraded and excreted by a cluster of phase II enzymes. Although not fully understood, some polymorphisms of these enzymes are known to lead to increased or decreased enzymatic activities, most likely causing inter-individual variations in the sensitivity to smoking[[44-49](#_ENREF_44)]. A better understanding of these mechanisms may identify individuals who are susceptible to lung cancer development when exposed to active or passive smoking. More recently, a decreased serum level of Crab (Clara) cell secretory protein (CC-16) has been found to increase the risk of both COPD[[50](#_ENREF_50)] and lung cancer[[51](#_ENREF_51)].

**PROGNOSIS**

As discussed above and illustrated in Table 1, a substantial proportion of patients with COPD die from lung cancer. The coexistence of lung cancer clearly worsens the prognosis of patients with COPD, but a discussion of how COPD worsens the outcome of patients with lung cancer and how this might be overcome is important.

The deterioration of pulmonary function together with the risk of acute exacerbation of COPD would, in theory, make invasive diagnostic procedures, surgery, radiotherapy and chemotherapy difficult in patients with lung cancer. A retrospective study by Sekine *et al* reported an increased rate of postoperative complications, including pneumonia and the need for a tracheostomy, increased cancer recurrence, and a decreased 5-year survival rate in patients with completely resected stage IA non-small cell lung cancer (NSCLC) and coexisting COPD; the 5-year survival rates of patients with COPD (*n* = 80) and of those without COPD (*n* = 362) were 77.0% and 91.6%, respectively (*P* = 0.0001)[[52](#_ENREF_52)]. A recent retrospective study involving 902 patients with stage IA to IIB NSCLC treated with surgical resection also disclosed that 63.4% (572/902) of the patient population had self-reported, physician-diagnosed COPD, and the patients with COPD had a poorer 5-year progression-free survival rate (50.1% *vs* 60.6%, *P* = 0.007) and a poorer 5-year overall survival rate (54.4% *vs* 69.0%, *P* = 0.0002) than the patients without COPD[[53](#_ENREF_53)].

**TREATMENT**

Treatment algorithms can be complex when different diseases coexist in the same patient. It seems reasonable to prioritize the treatment of diseases with a more serious impact on the prognosis: for example, the treatment for stage III small cell lung cancer would be given preference over the treatment for a coincidental low-grade prostatic cancer in the same patient. The situation, however, is totally different in patients with coexisting COPD and lung cancer. It is very important to diagnose, evaluate, and manage both the COPD and lung cancer in a comprehensive manner for the following reasons.

***To avoid the deterioration of quality of life because of COPD***

COPD symptoms significantly overlap with those of lung cancer. Cough, sputum, shortness of breath, body-weight loss, appetite loss, and even depression may arise from COPD rather than from lung cancer, in some cases. The appropriate treatment for COPD may relieve these symptoms, leading to an improved quality of life (QOL).

***To avoid the acute exacerbation of COPD during treatment for lung cancer***

The acute exacerbation of COPD can be precipitated by upper respiratory tract viral infections, bacterial infections of the tracheobronchial trees, and other factors. Once acute exacerbation has occurred, the mortality rate is high. In patients with COPD and lung cancer, stress or immunosuppression as a result of surgery, radiotherapy, chemotherapy, or a terminally ill status can act as predisposing factors for an acute exacerbation. It is particularly important to understand that COPD exacerbations can often be prevented with the appropriate management of the disease[[2](#_ENREF_2)].

***To decrease the complications associated with lung cancer treatment.***

Acute lung injury is a serious complication associated with lung cancer treatment, especially when patients suffer from symptomatic or asymptomatic idiopathic pulmonary fibrosis (IPF). Acute lung injury can occur in patients undergoing surgery, thoracic radiotherapy, or cytotoxic or molecular-targeted therapy[[54](#_ENREF_54), [55](#_ENREF_55)]. Although this complication seems to be more frequent in Japanese patients than in patients from other countries, the precise epidemiology and underlying mechanisms are not well known. In contrast to IPF, the presence of COPD is not recognized as a significant risk factor for acute lung injury associated with lung cancer treatment.

***To ameliorate the outcome of the surgical resection of lung cancer***

As a result of improvements in anesthesiology, surgical technique, and postoperative managements including rehabilitation, the curative-intent surgical resection of lung cancer in patients with COPD has become safer than previously expected[[56](#_ENREF_56)]. When a lung cancer is located within a severely damaged emphysematous region, its resection does not necessary impair pulmonary functions to the extent that a lung volume reduction surgery for severe emphysema would restore the impaired pulmonary function. In a study with a limited number of patients, Kobayashi *et al*[[57](#_ENREF_57)] demonstrated better postoperative pulmonary functions than expected, with improved preoperative symptoms and pulmonary function, in patients with treatment-naïve COPD and lung cancer who were treated with inhaled tiotropium, a long-acting anticholinergic bronchodilator, starting 2 wk prior to surgery. As limited resections of lung cancer often result in poor outcomes, a curative-intent standard resection is recommended even for patients with mild to moderate COPD, with the aid of early interventions including drug therapy and rehabilitation for COPD[[56](#_ENREF_56)].

**FUTURE DIRECTIONS**

Low-dose CT screening effectively detects 10-fold more lung cancers at earlier stages compared with screenings using conventional chest X-rays[[58](#_ENREF_58)]. As mentioned earlier, the NLST, a randomized trial involving subjects with a high risk of lung cancer, confirmed a 20% reduction in the lung cancer mortality among subjects allocated to a low-dose CT screening group compared with an X-ray screening group[[21](#_ENREF_21)]. This screening strategy targeting individuals at high risk was based on their smoking history and age. Sekine *et al*[[59](#_ENREF_59)] emphasized the importance of the early detection of COPD for the purpose of lung cancer screening and proposed CT screening for individuals with suspected COPD as a strategy to target individuals at high risk. Based on a quick questionnaire that collected information about age, smoking history, and chronic respiratory symptoms, they identified 878 individuals fulfilling the defined criteria out of 89100 participants (1.0%). A total of 567 of the 878 participants (64.6%) underwent further evaluation consisting of CT and spirometry, resulting in the detection of COPD in 161 participants, with 38.5% of them requiring COPD treatment[[60](#_ENREF_60)]. Although the data regarding lung cancer detection are not yet available because the trial is still ongoing, this strategy for identifying a high-risk population based on suspected COPD could be an alternative to identification strategies based on age and smoking history. We envision that this new approach could enable us to evaluate and manage COPD and lung cancer comprehensively at early stages and from screening through specialized treatment.

**REFERENCES**

1 World health organization fact sheets. Fact sheet N°297 Reviewed January 2013, available from http: //www.who.int/mediacentre/factsheets/fs297/en/

2 Global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD) 2013

3 **Halbert RJ**, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: what is the true burden of disease? *Chest* 2003; **123**: 1684-1692 [PMID: 12740290 DOI: 10.1378/chest.123.5.1684]

4 **Halbert RJ**, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. *Eur Respir J* 2006; **28**: 523-532 [PMID: 16611654 DOI: 10.1183/09031936.06.00124605]

5 **Mathers CD**, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med* 2006; **3**: e442 [PMID: 17132052 DOI: 10.1371/journal.pmed.0030442]

6 **Adcock IM**, Caramori G, Barnes PJ. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. *Respiration* 2011; **81**: 265-284 [PMID: 21430413 DOI: 10.1159/000324601]

7 **Houghton AM**, Mouded M, Shapiro SD. Common origins of lung cancer and COPD. *Nat Med* 2008; **14**: 1023-1024 [PMID: 18841139 DOI: 10.1038/nm1008-1023]

8 **Antonelli Incalzi R**, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, Pistelli R. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. *Eur Respir J* 1997; **10**: 2794-2800 [PMID: 9493663 DOI: 10.1183/09031936.97.10122794]

9 **Celli BR**, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med* 2004; **350**: 1005-1012 [PMID: 14999112 DOI: 10.1056/NEJMoa021322]

10 **Garcia-Aymerich J**, Farrero E, Félez MA, Izquierdo J, Marrades RM, Antó JM. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. *Thorax* 2003; **58**: 100-105 [PMID: 12554887 DOI: 10.1136/thorax.58.2.100]

11 **Górecka D**, Gorzelak K, Sliwiński P, Tobiasz M, Zieliński J. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. *Thorax* 1997; **52**: 674-679 [PMID: 9337824 DOI: 10.1136/thx.52.8.674]

12 **Keistinen T**, Tuuponen T, Kivelä SL. Survival experience of the population needing hospital treatment for asthma or COPD at age 50-54 years. *Respir Med* 1998; **92**: 568-572 [PMID: 9692124 DOI: 10.1016/S0954-6111(98)90310-9]

13 **Pauwels RA**, Löfdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. *N Engl J Med* 1999; **340**: 1948-1953 [PMID: 10379018 DOI: 10.1056/NEJM199906243402503]

14 **Vilkman S**, Keistinen T, Tuuponen T, Kivelä SL. Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. *Respiration* 1997; **64**: 281-284 [PMID: 9257363 DOI: 10.1159/000196687]

15 **Zieliński J**. Circumstances of death in chronic obstructive pulmonary disease. *Monaldi Arch Chest Dis* 1998; **53**: 324-330 [PMID: 9785820 DOI: ]

16 **Anthonisen NR**, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. *Ann Intern Med* 2005; **142**: 233-239 [PMID: 15710956 DOI: 10.7326/0003-4819-142-4-200502150-00005]

17 **Skillrud DM**, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. *Ann Intern Med* 1986; **105**: 503-507 [PMID: 3752756 DOI: 10.7326/0003-4819-105-4-503]

18 **Kuller LH**, Ockene J, Meilahn E, Svendsen KH. Relation of forced expiratory volume in one second (FEV1) to lung cancer mortality in the Multiple Risk Factor Intervention Trial (MRFIT). *Am J Epidemiol* 1990; **132**: 265-274 [PMID: 2372006]

19 **Turner MC**, Chen Y, Krewski D, Calle EE, Thun MJ. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. *Am J Respir Crit Care Med* 2007; **176**: 285-290 [PMID: 17478615 DOI: 10.1164/rccm.200612-1792OC]

20 **Wasswa-Kintu S**, Gan WQ, Man SF, Pare PD, Sin DD. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. *Thorax* 2005; **60**: 570-575 [PMID: 15994265 DOI: 10.1136/thx.2004.037135]

21 **Aberle DR**, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011; **365**: 395-409 [PMID: 21714641 DOI: 10.1056/NEJMoa1102873]

22 **Field JK**, Hansell DM, Duffy SW, Baldwin DR. CT screening for lung cancer: countdown to implementation. *Lancet Oncol* 2013; **14**: e591-e600 [PMID: 24275132 DOI: 10.1016/S1470-2045(13)70293-6]

23 **Goddard PR**, Nicholson EM, Laszlo G, Watt I. Computed tomography in pulmonary emphysema. *Clin Radiol* 1982; **33**: 379-387 [PMID: 7083738 DOI: 10.1016/S0009-9260(82)80301-2]

24 **de Torres JP**, Bastarrika G, Wisnivesky JP, Alcaide AB, Campo A, Seijo LM, Pueyo JC, Villanueva A, Lozano MD, Montes U, Montuenga L, Zulueta JJ. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. *Chest* 2007; **132**: 1932-1938 [PMID: 18079226 DOI: 10.1378/chest.07-1490]

25 **Wilson DO**, Weissfeld JL, Balkan A, Schragin JG, Fuhrman CR, Fisher SN, Wilson J, Leader JK, Siegfried JM, Shapiro SD, Sciurba FC. Association of radiographic emphysema and airflow obstruction with lung cancer. *Am J Respir Crit Care Med* 2008; **178**: 738-744 [PMID: 18565949 DOI: 10.1164/rccm.200803-435OC]

26 **Mizuno S**, Takiguchi Y, Fujikawa A, Motoori K, Tada Y, Kurosu K, Sekine Y, Yanagawa N, Hiroshima K, Muraoka K, Mitsushima T, Niki N, Tanabe N, Tatsumi K, Kuriyama T. Chronic obstructive pulmonary disease and interstitial lung disease in patients with lung cancer. *Respirology* 2009; **14**: 377-383 [PMID: 19192220 DOI: 10.1111/j.1440-1843.2008.01477.x]

27 **Maldonado F**, Bartholmai BJ, Swensen SJ, Midthun DE, Decker PA, Jett JR. Are airflow obstruction and radiographic evidence of emphysema risk factors for lung cancer? A nested case-control study using quantitative emphysema analysis. *Chest* 2010; **138**: 1295-1302 [PMID: 20348193 DOI: 10.1378/chest.09-2567]

28 **Li Y**, Swensen SJ, Karabekmez LG, Marks RS, Stoddard SM, Jiang R, Worra JB, Zhang F, Midthun DE, de Andrade M, Song Y, Yang P. Effect of emphysema on lung cancer risk in smokers: a computed tomography-based assessment. *Cancer Prev Res (Phila)* 2011; **4**: 43-50 [PMID: 21119049 DOI: 10.1158/1940-6207.CAPR-10-0151]

29 **Wilson DO**, Leader JK, Fuhrman CR, Reilly JJ, Sciurba FC, Weissfeld JL. Quantitative computed tomography analysis, airflow obstruction, and lung cancer in the pittsburgh lung screening study. *J Thorac Oncol* 2011; **6**: 1200-1205 [PMID: 21610523 DOI: 10.1097/JTO.0b013e318219aa93]

30 **Zurawska JH**, Jen R, Lam S, Coxson HO, Leipsic J, Sin DD. What to do when a smoker's CT scan is "normal"?: Implications for lung cancer screening. *Chest* 2012; **141**: 1147-1152 [PMID: 22553261 DOI: 10.1378/chest.11-1863]

31 **Young RP**, Hopkins RJ. How the genetics of lung cancer may overlap with COPD. *Respirology* 2011; **16**: 1047-1055 [PMID: 21749550 DOI: 10.1111/j.1440-1843.2011.02019.x]

32 **Vakkila J**, Lotze MT. Inflammation and necrosis promote tumour growth. *Nat Rev Immunol* 2004; **4**: 641-648 [PMID: 15286730 DOI: 10.1038/nri1415]

33 **Luo J**, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. *Cell* 2009; **136**: 823-837 [PMID: 19269363 DOI: 10.1016/j.cell.2009.02.024]

34 **Negrini S**, Gorgoulis VG, Halazonetis TD. Genomic instability--an evolving hallmark of cancer. *Nat Rev Mol Cell Biol* 2010; **11**: 220-228 [PMID: 20177397 DOI: 10.1038/nrm2858]

35 **Parimon T**, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2007; **175**: 712-719 [PMID: 17185647 DOI: 10.1164/rccm.200608-1125OC]

36 **Kratz JR**, Yagui-Beltrán A, Jablons DM. Cancer stem cells in lung tumorigenesis. *Ann Thorac Surg* 2010; **89**: S2090-S2095 [PMID: 20493987 DOI: 10.1016/j.athoracsur.2010.03.038]

37 **Kim CF**, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT, Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. *Cell* 2005; **121**: 823-835 [PMID: 15960971 DOI: 10.1016/j.cell.2005.03.032]

38 **Kim CF**. Paving the road for lung stem cell biology: bronchioalveolar stem cells and other putative distal lung stem cells. *Am J Physiol Lung Cell Mol Physiol* 2007; **293**: L1092-L1098 [PMID: 17693488 DOI: 10.1152/ajplung.00015.2007]

39 **Sun Z**, Yang P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. *Lancet Oncol* 2004; **5**: 182-190 [PMID: 15003202 DOI: 10.1016/S1470-2045(04)01414-7]

40 **Topic AS**, Jelic-Ivanovic ZD, Spasojevic-Kalimanovska VV, Spasic SM. Association of moderate alpha-1 antitrypsin deficiency with lung cancer in the Serbian population. *Arch Med Res* 2006; **37**: 866-870 [PMID: 16971227 DOI: 10.1016/j.arcmed.2006.05.006]

41 **Yang P**, Bamlet WR, Sun Z, Ebbert JO, Aubry MC, Krowka MJ, Taylor WR, Marks RS, Deschamps C, Swensen SJ, Wieben ED, Cunningham JM, Melton LJ, de Andrade M. Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk. *Chest* 2005; **128**: 445-452 [PMID: 16002971 DOI: 10.1378/chest.128.1.445]

42 **Yang P**, Sun Z, Krowka MJ, Aubry MC, Bamlet WR, Wampfler JA, Thibodeau SN, Katzmann JA, Allen MS, Midthun DE, Marks RS, de Andrade M. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. *Arch Intern Med* 2008; **168**: 1097-1103 [PMID: 18504338 DOI: 10.1001/archinte.168.10.1097]

43 **El-Akawi ZJ**, Nusier MK, Zoughool FE. Relationship between alpha-1 antitrypsin deficient genotypes S and Z and lung cancer in Jordanian lung cancer patients. *Saudi Med J* 2006; **27**: 181-184 [PMID: 16501672]

44 **Bartsch H**, Petruzzelli S, De Flora S, Hietanen E, Camus AM, Castegnaro M, Geneste O, Camoirano A, Saracci R, Giuntini C. Carcinogen metabolism and DNA adducts in human lung tissues as affected by tobacco smoking or metabolic phenotype: a case-control study on lung cancer patients. *Mutat Res* 1991; **250**: 103-114 [PMID: 1944327 DOI: 10.1016/0027-5107(91)90167-M]

45 **Georgiadis P**, Demopoulos NA, Topinka J, Stephanou G, Stoikidou M, Bekyrou M, Katsouyianni K, Sram R, Autrup H, Kyrtopoulos SA. Impact of phase I or phase II enzyme polymorphisms on lymphocyte DNA adducts in subjects exposed to urban air pollution and environmental tobacco smoke. *Toxicol Lett* 2004; **149**: 269-280 [PMID: 15093273 DOI: 10.1016/j.toxlet.2003.12.038]

46 **Helmig S**, Hadzaad B, Döhrel J, Schneider J. Influence of the Cyp1B1 L432V gene polymorphism and exposure to tobacco smoke on Cyp1B1 mRNA expression in human leukocytes. *Drug Metab Dispos* 2009; **37**: 1490-1495 [PMID: 19349377 DOI: 10.1124/dmd.109.027060]

47 **Kiyohara C**, Yoshimasu K, Takayama K, Nakanishi Y. EPHX1 polymorphisms and the risk of lung cancer: a HuGE review. *Epidemiology* 2006; **17**: 89-99 [PMID: 16357600 DOI: 10.1097/01.ede.0000187627.70026.23]

48 **Mota P**, Moura DS, Vale MG, Coimbra H, Carvalho L, Regateiro F. CYP1A1 m1 and m2 polymorphisms: genetic susceptibility to lung cancer. *Rev Port Pneumol* 2010; **16**: 89-98 [PMID: 20054510]

49 **Wenzlaff AS**, Cote ML, Bock CH, Land SJ, Santer SK, Schwartz DR, Schwartz AG. CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. *Carcinogenesis* 2005; **26**: 2207-2212 [PMID: 16051642 DOI: 10.1093/carcin/bgi191]

50 **Park HY**, Churg A, Wright JL, Li Y, Tam S, Man SF, Tashkin D, Wise RA, Connett JE, Sin DD. Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2013; **188**: 1413-1419 [PMID: 24245748 DOI: 10.1164/rccm.201305-0892OC]

51 Guerra S, Vasquez MM, Spangenberg A, Halonen M, Martinez FD. Serum concentrations of club cell secretory protein (clara) and cancer mortality in adults: A population-based, prospective cohort study. Lancet Respir Med 2013; 1: 779-785 [PMID: , DOI: 10.1016/S2213-2600(13)70220-0]

52 **Sekine Y**, Yamada Y, Chiyo M, Iwata T, Nakajima T, Yasufuku K, Suzuki M, Fujisawa T. Association of chronic obstructive pulmonary disease and tumor recurrence in patients with stage IA lung cancer after complete resection. *Ann Thorac Surg* 2007; **84**: 946-950 [PMID: 17720404 DOI: 10.1016/j.athoracsur.2007.04.038]

53 **Zhai R**, Yu X, Shafer A, Wain JC, Christiani DC. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. *Chest* 2014; **145**: 346-353 [PMID: 24008835 DOI: 10.1378/chest.13-1176]

54 **Minegishi Y**, Takenaka K, Mizutani H, Sudoh J, Noro R, Okano T, Azuma A, Yoshimura A, Ando M, Tsuboi E, Kudoh S, Gemma A. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. *Intern Med* 2009; **48**: 665-672 [PMID: 19420811 DOI: 10.2169/internalmedicine.48.1650]

55 **Gemma A**. Drug-induced interstitial lung disease (DILD) in molecular targeted therapy. *Int J Clin Oncol* 2012; **17**: 533 [PMID: 23152006 DOI: 10.1007/s10147-012-0495-4]

56 **Raviv S**, Hawkins KA, DeCamp MM, Kalhan R. Lung cancer in chronic obstructive pulmonary disease: enhancing surgical options and outcomes. *Am J Respir Crit Care Med* 2011; **183**: 1138-1146 [PMID: 21177883 DOI: 10.1164/rccm.201008-1274CI]

57 **Kobayashi S**, Suzuki S, Niikawa H, Sugawara T, Yanai M. Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPD. *Respirology* 2009; **14**: 675-679 [PMID: 19476597 DOI: 10.1111/j.1440-1843.2009.01543.x]

58 **Fujikawa A**, Takiguchi Y, Mizuno S, Uruma T, Suzuki K, Nagao K, Niijima M, Edo H, Hino M, Kuriyama T. Lung cancer screening--comparison of computed tomography and X-ray. *Lung Cancer* 2008; **61**: 195-201 [PMID: 18242764 DOI: 10.1016/j.lungcan.2007.12.010]

59 **Sekine Y**, Katsura H, Koh E, Hiroshima K, Fujisawa T. Early detection of COPD is important for lung cancer surveillance. *Eur Respir J* 2012; **39**: 1230-1240 [PMID: 22088970 DOI: 10.1183/09031936.00126011]

60 **Sekine Y**, Fujisawa T, Suzuki K, Tsutatani S, Kubota K, Ikegami H, Isobe Y, Nakamura M, Takiguchi Y, Tatsumi K. Detection of chronic obstructive pulmonary disease in community-based annual lung cancer screening: Chiba Chronic Obstructive Pulmonary Disease Lung Cancer Screening Study Group. *Respirology* 2014; **19**: 98-104 [PMID: 24033868 DOI: 10.1111/resp.12179]

**P-Reviewer:** Driscoll D **S-Editor:** Wen LL  **L-Editor:**  **E-Editor:**

**Table 1 Major causes of death reported in patients with chronic obstructive pulmonary disease**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author** |  | **Vilkman *et al*[12]** | **Garecka *et al*[9]** | **Antonelli Incalzi *et al*[6]** | **Zielinski *et al*[13]** | **Keistinen *et al*[10]** | **Pauwel *et al*[11]** | **Garcia-Aymerich *et al*[8]** | **Celli *et al*[7]** | **Anthonisen *et al*[14]** |
| **Publication year** | | **1997** | **1997** | **1997** | **1997** | **1998** | **1999** | **2003** | **2004** | **2005** |
| Total No. of COPD | | 2237 | 135 | 270 | 215 | 2727 | 1277 | 340 | 625 | 5887 |
| Total deaths | | 1070 | 70 | 228 | 215 | 973 | 18 | 98 | 162 | 731 |
| Cause of death (%)1 | | |  |  |  |  |  |  |  |  |
|  | COPD2 | 30 | 61 | 63 | 49 | 22 | 6 | 74 | 61 | 8 |
|  | Lung cancer | 12 | 4 | 5 | 7 | 13 | 33 | 5 | 12 | 33 |
|  | Other cancer | 8 | 4 | 4 | ND | 8 | 6 | 2 | ND | 21 |
|  | Cardiovascular | 33 | 6 | 16 | 37 | 32 | 39 | 12 | 14 | 22 |
|  | Others | 17 | 24 | 12 | 7 | 25 | 17 | 6 | 13 | 16 |

1Calculated from the data reported by each literature; 2Including respiratory causes, respiratory failure, respiratory infection. Pulmonary embolism was included in cardiovascular cause. ND: Not described; COPD: Chronic obstructive pulmonary disease.

**Table 2 Odds ratios for coincidental lung cancer based on factors indicative of hronic obstructive pulmonary disease or interstitial lung diseases, according to smoking status1**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **FEV1/FVC < 70%** | **%VC < 80%** | **LAA score ≥12** | **Fibrosis score ≥ 1** | **GGA score ≥1** |
| Never smoker (*n =* 284) | 10.42 (2.82-38.55)3 | 2.02 (0.42-9.86) | 0.98 (0.21-4.43) | 6.39 (2.13-19.18) | 2.32 (0.80-6.71) |
| Ex-smoker (*n =* 101) | 5.89 (2.02-17.22) | No data4 | 3.43 (1.50-7.85) | 3.94 (1.20-12.88) | 3.59 (1.09-11.80) |
| Current smoker (*n =* 179) | 7.456 (3.48-15.95) | 2.25 (0.62-8.11) | 5.07 (2.51-10.28) | 5.45 (2.39-12.44) | 2.48 (1.06-5.77) |
| Total (*n =* 564) | 7.17 (4.03-12.74) | 4.73 (2.00-11.17) | 3.63 (2.24-5.89) | 5.10 (2.82-9.24) | 2.71 (1.52-4.81) |

1See the reference by Mizuno *et al*[24] for details; 2Low attenuation area (LAA) was assesed using Goddard's scoring system: fibrosis and ground glass attenuation (GGA) were assessed using Kazzerooni's scoring system; 3Numbers in parentheses indicate 95%CI; 4No data calculated because of insufficient number.